Moore Capital Management’s Insmed INSM Stock Holding History

Moore Capital Management’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-100,000	Closed	-$2.52M	–	491
2023 Q3	$2.52M	Buy	+100,000	New	+$2.29M	0.05%	238

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Moore Capital Management's INSM Position: Q3 2024 in Review

Moore Capital Management sold out of Insmed (INSM) in Q3 2024, closing a stake of 5,000 shares — an estimated $335K sold.

Moore Capital Management first reported a position in INSM in Q2 2017 and held it in 8 quarters. The position peaked at $2.58M in Q3 2022. 413 funds tracked by Wall St. Rank hold INSM as of Q3 2024.

Moore Capital Management reported no remaining Insmed position as of Q3 2024 after selling out during the quarter.
Moore Capital Management sold 5,000 Insmed shares in Q3 2024, an estimated $335K.
Moore Capital Management first reported a position in Insmed in Q2 2017 and held it in 8 quarters.
Moore Capital Management's Insmed position peaked at $2.58M in Q3 2022.
413 funds tracked by Wall St. Rank held Insmed as of Q3 2024.

Based on Moore Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.